


## Ohio Administrative Code


Rule 4723-9-02 Requirements for a course of study in advanced pharmacology.

Effective: February 1, 2021

- (A) To be acceptable to the board, a course of study shall meet the following requirements:
- (1) Be a minimum of forty-five contact hours in length and include content which ensures sufficient preparation for the safe and effective prescribing of drugs and therapeutic devices;
- (2) Include content which is specific to the participant's nursing specialty and which includes all of the following:
- (a) A minimum of thirty-six hours of training, obtained from a single provider, in:
- (i) Pharmacokinetic principles and clinical application; and
- (ii) Principles of the use of drugs and therapeutic devices in the prevention of illness and maintenance of health;
- (b) The fiscal and ethical implications of prescribing drugs and therapeutic devices;
- (c) The state and federal laws that apply to the authority to prescribe;
- (d) Instruction that is specific to schedule II controlled substances, including instruction in all of the following:
- (i) Indications and contraindications for the use of schedule II controlled substances in drug therapies, including risk, evaluation and mitigation strategies for the use of opiates in the management of acute, sub-acute and chronic pain, as those terms are defined in rule 4723-9-10 of the Administrative Code, for non-terminal conditions, and the need for periodic assessment and documentation of the patients functional status;



- (ii) The most recent guidelines and recommendations for pain management therapies and education, as established by state and national organizations such as the Ohio pain initiative, the American pain society, the governor's recoveryOhio initiative,, and the United States food and drug administration (FDA), and the centers for disease control (CDC);
- (iii) The most recent guidelines and recommendations for stimulant therapies utilized in the management of attention-deficit or hyperactivity disorder, as adopted by state and national organizations;
- (iv) Fiscal and ethical implications of prescribing schedule II controlled substances;
- (v) State and federal laws that apply to the authority to prescribe schedule II controlled substances, including state medical board of Ohio rules governing controlled substances and the treatment of chronic pain, and Ohio state board of pharmacy rules governing the manner of issuance of a prescription, and rules set forth in Chapters 4723-1 to 4723-27 of the Administrative Code;
- (vi) Prevention of abuse and diversion of schedule II controlled substances, including identification of the risk of abuse, addiction and diversion, recognition of abuse, addiction and diversion, types of assistance available for prevention of abuse, addiction and diversion, the use of the Ohio automated rx reporting system (OARRS), including standards and procedures for OARRS access and review established in section 4729.75 of the Revised Code and rule 4723-9-12 of the Administrative Code, and other methods of establishing safeguards against abuse and diversion; and
- (e) Instruction specific to schedule II controlled substances as set forth in paragraph (A)(2)(d) of this rule may be integrated with areas of instruction required by paragraphs (A)(2)(a), (A)(2)(b) and (A)(2)(c) of this rule.
- (3) Include a process for interaction of the participants with instructional personnel;
- (4) Include a process for evaluating the participants' learning of the content required by this rule; and
- (5) May be provided online, but must be faculty-directed or independent study and, as defined in



rule 4723-14-01 of the Administrative Code, is offered by either an accredited educational institution acceptable to the board or a continuing education course that meets the requirements of Chapter 4723-14 of the Administrative Code.